Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 7.4.2.2 - ABC-type nonpolar-amino-acid transporter

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
abc-type nonpolar-amino-acid transporter deficiency
Interdependence of thyroglobulin processing and thyroid hormone export in the mouse thyroid gland.
The Amino Acid Transporter Mct10/Tat1 Is Important to Maintain the TSH Receptor at Its Canonical Basolateral Localization and Assures Regular Turnover of Thyroid Follicle Cells in Male Mice.
The L-type amino acid transporter LAT1 inhibits osteoclastogenesis and maintains bone homeostasis through the mTORC1 pathway.
Acidosis
Metabolic acidosis in sheep alters expression of renal and skeletal muscle amino acid enzymes and transporters.
Adenocarcinoma
A novel five-antibody immunohistochemical test for subclassification of lung carcinoma.
Genome Wide Methylome Alterations in Lung Cancer.
Identification of featured biomarkers in different types of lung cancer with DNA microarray.
Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma.
Argininosuccinic Aciduria
Ascorbic acid prevents acetaminophen-induced hepatotoxicity in mice by ameliorating glutathione recovery and autophagy.
Arthritis, Experimental
System A amino acid transporters regulate glutamine uptake and attenuate antibody-mediated arthritis.
Arthritis, Rheumatoid
Intervening upregulated SLC7A5 could mitigate inflammatory mediator by mTOR-P70S6K signal in rheumatoid arthritis synoviocytes.
Brain Neoplasms
Quantitative protein expression of blood-brain barrier transporters in the vasculature of brain metastases of patients with lung and breast cancer.
Breast Neoplasms
Amino acid transporters as emerging therapeutic targets in cancer.
LLGL2 rescues nutrient stress by promoting leucine uptake in ER+ breast cancer.
Molecular expression and functional activity of efflux and influx transporters in hypoxia induced retinal pigment epithelial cells.
SLC7A5 serves as a prognostic factor of breast cancer and promotes cell proliferation through activating AKT/mTORC1 signaling pathway.
The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
Carcinogenesis
SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC.
The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer.
Carcinoma
A novel five-antibody immunohistochemical test for subclassification of lung carcinoma.
AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis.
Expression of the neutral amino acids transporter ASCT1 in esophageal carcinomas.
Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma.
Carcinoma, Basal Cell
Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma.
Carcinoma, Ductal
Single-cell heterogeneity in ductal carcinoma in situ of breast.
Carcinoma, Hepatocellular
Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Single-cell heterogeneity in ductal carcinoma in situ of breast.
Carcinoma, Squamous Cell
A novel five-antibody immunohistochemical test for subclassification of lung carcinoma.
AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis.
Cerebellar Ataxia
ACE2 and gut amino acid transport.
Cerebrovascular Disorders
Altered cargo proteins of human plasma endothelial cell-derived exosomes in atherosclerotic cerebrovascular disease.
Cholangiocarcinoma
Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment.
Choriocarcinoma
Cloning of the sodium-dependent, broad-scope, neutral amino acid transporter Bo from a human placental choriocarcinoma cell line.
Colonic Neoplasms
MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer.
[miR-126 inhibits colon cancer proliferation and invasion through targeting IRS1, SLC7A5 and TOM1 gene].
Colorectal Neoplasms
LINC00857 promotes cell proliferation and migration in colorectal cancer by interacting with YTHDC1 and stabilizing SLC7A5.
The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer.
COVID-19
An overview of the gut side of the SARS-CoV-2 infection.
Low temperature bacterial expression of the neutral amino acid transporters SLC1A5 (ASCT2), and SLC6A19 (B0AT1).
Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.
Cystinuria
Heterodimeric amino acid transporter glycoprotein domains determining functional subunit association.
Dehydration
DNA methylation-mediated modulation of rapid desiccation tolerance acquisition and dehydration stress memory in the resurrection plant Boea hygrometrica.
Diabetes Mellitus, Type 2
Mice lacking neutral amino acid transporter B(0)AT1 (Slc6a19) have elevated levels of FGF21 and GLP-1 and improved glycaemic control.
Endometrial Neoplasms
High throughput silencing identifies novel genes in endometrioid endometrial cancer.
OIP5-AS1 contributes to the development in endometrial carcinoma cells by targeting miR-152-3p to up-regulate SLC7A5.
Enteritis
Cyclooxygenase pathway mediates the inhibition of Na-glutamine co-transporter B0AT1 in rabbit villus cells during chronic intestinal inflammation.
Mast cell regulation of Na-glutamine co-transporters B0AT1 in villus and SN2 in crypt cells during chronic intestinal inflammation.
Regulation of sodium-glutamine cotransport in villus and crypt cells by glucocorticoids during chronic enteritis.
Epilepsy
Assessment of Autism Zebrafish Mutant Models Using a High-Throughput Larval Phenotyping Platform.
Euthyroid Sick Syndromes
Expression of Thyroid Hormone Transporters during Critical Illness.
Exanthema
ACE2 and gut amino acid transport.
Fatty Liver
Novel Chemical Scaffolds to Inhibit the Neutral Amino Acid Transporter B0AT1 (SLC6A19), a Potential Target to Treat Metabolic Diseases.
Fetal Growth Retardation
Expression of thyroid hormone transporters in the human placenta and changes associated with intrauterine growth restriction.
Glioblastoma
Protein Expression and Functional Relevance of Efflux and Uptake Drug Transporters at the Blood-Brain Barrier of Human Brain and Glioblastoma.
Regulation of branched-chain amino acid metabolism by hypoxia-inducible factor in glioblastoma.
Glioma
Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98).
Targeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids.
Hartnup Disease
Accurate discrimination of Hartnup disorder from other aminoacidurias using a diagnostic ratio.
ACE2 and gut amino acid transport.
Defective intestinal amino acid absorption in Ace2 null mice.
Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19.
Hartnup disorder: polymorphisms identified in the neutral amino acid transporter SLC1A5.
Hartnup disorder: unraveling the mystery.
Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors.
Identification and Characterization of Inhibitors of a Neutral Amino Acid Transporter, SLC6A19, Using Two Functional Cell-Based Assays.
Molecular cloning of mouse amino acid transport system B0, a neutral amino acid transporter related to Hartnup disorder.
Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder.
Novel renal amino acid transporters.
The molecular basis of neutral aminoacidurias.
The role of the neutral amino acid transporter B0AT1 (SLC6A19) in Hartnup disorder and protein nutrition.
Hepatitis C
Requirement of rRNA methylation for 80S ribosome assembly on a cohort of cellular internal ribosome entry sites.
Hyperpigmentation
Regulation of Melanogenesis by the Amino Acid Transporter SLC7A5.
Hyperthyroidism
Differences in Mouse Hepatic Thyroid Hormone Transporter Expression with Age and Hyperthyroidism.
Infections
Forecasting the timeframe of 2019-nCoV and human cells interaction with reverse engineering.
Intracellular multiplication of Legionella pneumophila depends on host cell amino acid transporter SLC1A5.
Microarray analysis reveals the inhibition of intestinal expression of nutrient transporters in piglets infected with porcine epidemic diarrhea virus.
Role of BrnQ1 and BrnQ2 in Branched-Chain Amino Acid Transport and Virulence in Staphylococcus aureus.
The Amino Acid-mTORC1 Pathway Mediates APEC TW-XM-Induced Inflammation in bEnd.3 Cells.
The role of two branched-chain amino acid transporters in Staphylococcus aureus growth, membrane fatty acid composition, and virulence.
Inflammatory Bowel Diseases
ACE2 and gut amino acid transport.
Insulin Resistance
Role of the Neutral Amino Acid Transporter SLC7A10 in Adipocyte Lipid Storage, Obesity, and Insulin Resistance.
Intellectual Disability
Assessment of Autism Zebrafish Mutant Models Using a High-Throughput Larval Phenotyping Platform.
Iron Deficiencies
Metabolic requirements of NK cells during the acute response against retroviral infection.
Liver Neoplasms
Co-regulatory Network of Oncosuppressor miRNAs and Transcription Factors for Pathology of Human Hepatic Cancer Stem Cells (HCSC).
Lung Neoplasms
Identification of featured biomarkers in different types of lung cancer with DNA microarray.
miR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5.
Malnutrition
Moderate Alcohol Consumption Inhibits Sodium-Dependent Glutamine Co-Transport in Rat Intestinal Epithelial Cells in Vitro and Ex Vivo.
Melanoma
MAPK signaling regulates c-MYC for melanoma cell adaptation to asparagine restriction.
Metabolic Diseases
Novel Chemical Scaffolds to Inhibit the Neutral Amino Acid Transporter B0AT1 (SLC6A19), a Potential Target to Treat Metabolic Diseases.
Mouth Neoplasms
Application of Random Forest and data integration identifies three dysregulated genes and enrichment of Central Carbon Metabolism pathway in Oral Cancer.
Mucositis
Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial.
Multiple Myeloma
A Single Nucleotide Polymorphism in SLC7A5 is Associated with Gastrointestinal Toxicity after High-Dose Melphalan and Autologous Stem Cell Transplantation for Multiple Myeloma.
A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients.
Myelodysplastic Syndromes
SLC7A5 act as a potential leukemic transformation target gene in myelodysplastic syndrome.
Neoplasm Metastasis
GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis.
SLC7A5 Functions as a Downstream Target Modulated by CRKL in Metastasis Process of Gastric Cancer SGC-7901 Cells.
Neoplasms
18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy.
Ablation of the ASCT2 (SLC1A5) gene encoding a neutral amino acid transporter reveals transporter plasticity and redundancy in cancer cells.
Amino acid transporters as emerging therapeutic targets in cancer.
Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs.
Antitumor effect of dimethyl itaconate on thymic carcinoma by targeting LDHA-mTOR axis.
AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis.
Application of Random Forest and data integration identifies three dysregulated genes and enrichment of Central Carbon Metabolism pathway in Oral Cancer.
Assessment of treatment response by autoradiography with (14)C-aminocyclopentane carboxylic acid, (67)Ga-DTPA, and (18)F-FDG in a herpes simplex virus thymidine kinase/ganciclovir brain tumor model.
Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma.
CircZNF124 regulates cell proliferation, leucine uptake, migration and invasion by miR-199b-5p/SLC7A5 pathway in endometrial cancer.
Discovery of Potent Inhibitors for the Large Neutral Amino Acid Transporter 1 (LAT1) by Structure-Based Methods.
Expression of neutral amino acid transporter ASCT2 in human prostate.
Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma.
GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis.
Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment.
Low temperature bacterial expression of the neutral amino acid transporters SLC1A5 (ASCT2), and SLC6A19 (B0AT1).
Methio "mine"! Cancer cells steal methionine and impair CD8 T-cell function.
miR-126 in human cancers: clinical roles and current perspectives.
MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer.
Potent-By-Design: Amino Acids Mimicking Porous Nanotherapeutics with Intrinsic Anticancer Targeting Properties.
PPAR? promotes tumor progression via activation of Glut1 and SLC1-A5 transcription.
Role of SLC7A5 in Metabolic Reprogramming of Human Monocyte/Macrophage Immune Responses.
Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma.
SLC6A15 acts as a tumor suppressor to inhibit migration and invasion in human papillary thyroid cancer.
SLC7A5 serves as a prognostic factor of breast cancer and promotes cell proliferation through activating AKT/mTORC1 signaling pathway.
Spherical cell shape of FLC-4 cell, a human hepatoma cell, enhances hepatocyte-specific function and suppresses tumor phenotype through the integration of mRNA-microRNA interaction.
Targeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids.
The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer.
The role of large neutral amino acid transporter (LAT1) in cancer.
Tumor suppressive miR-6775-3p inhibits ESCC progression through forming a positive feedback loop with p53 via MAGE-A family proteins.
Tumor Suppressor miR-184 Enhances Chemosensitivity by Directly Inhibiting SLC7A5 in Retinoblastoma.
Xenopus slc7a5 is essential for notochord function and eye development.
Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.
[Effect of SLC7A5 on the proliferation of tumor cells and its relationship with transforming growth factor-?1 ?signal pathway].
Neuroendocrine Tumors
Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Neutropenia
Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial.
Obesity
Carriership of the rs113883650/rs2287120 haplotype of the SLC7A5 (LAT1) gene increases the risk of obesity in infants with phenylketonuria.
Hypoxic Stress Upregulates the Expression of Slc38a1 in Brown Adipocytes via Hypoxia-Inducible Factor-1?.
Inhibition of SNAT5 Induces Incretin-Responsive State From Incretin-Unresponsive State in Pancreatic ?-Cells: Study of ?-Cell Spheroid Clusters as a Model.
Natural Autoimmunity to the Thyroid Hormone Monocarboxylate Transporters MCT8 and MCT10.
Role of the Neutral Amino Acid Transporter SLC7A10 in Adipocyte Lipid Storage, Obesity, and Insulin Resistance.
Osteoporosis
The L-type amino acid transporter LAT1 inhibits osteoclastogenesis and maintains bone homeostasis through the mTORC1 pathway.
Overweight
Carriership of the rs113883650/rs2287120 haplotype of the SLC7A5 (LAT1) gene increases the risk of obesity in infants with phenylketonuria.
Phenylketonurias
Carriership of the rs113883650/rs2287120 haplotype of the SLC7A5 (LAT1) gene increases the risk of obesity in infants with phenylketonuria.
Human LAT1 single nucleotide polymorphism N230K does not alter phenylalanine transport.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy.
Premature Birth
Maternal and placental responses before preterm birth: adaptations to increase fetal thyroid hormone availability?
Prostatic Neoplasms
Functional characterization and molecular expression of large neutral amino acid transporter (LAT1) in human prostate cancer cells [Int. J. Pharm. 443 (2013) 245-253].
Functional characterization and molecular expression of large neutral amino acid transporter (LAT1) in human prostate cancer cells.
Pulmonary Edema
Sodium coupled neutral amino acid transporter SNAT2 counteracts cardiogenic pulmonary edema by driving alveolar fluid clearance.
Retinoblastoma
Tumor Suppressor miR-184 Enhances Chemosensitivity by Directly Inhibiting SLC7A5 in Retinoblastoma.
Sarcoma
The use of protein-DNA, chromatin immunoprecipitation, and transcriptome arrays to describe transcriptional circuits in the dehydrated male rat hypothalamus.
Skin Neoplasms
Potent-By-Design: Amino Acids Mimicking Porous Nanotherapeutics with Intrinsic Anticancer Targeting Properties.
Small Cell Lung Carcinoma
Identification of featured biomarkers in different types of lung cancer with DNA microarray.
miR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5.
Squamous Cell Carcinoma of Head and Neck
AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis.
Starvation
Amino acid starvation induces the SNAT2 neutral amino acid transporter by a mechanism that involves eukaryotic initiation factor 2alpha phosphorylation and cap-independent translation.
Stomach Neoplasms
Anti-tumor efficacy evaluation of a novel monoclonal antibody targeting neutral amino acid transporter ASCT2 using patient-derived xenograft mouse models of gastric cancer.
GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis.
SLC7A5 Functions as a Downstream Target Modulated by CRKL in Metastasis Process of Gastric Cancer SGC-7901 Cells.
Thyroid Diseases
Natural Autoimmunity to the Thyroid Hormone Monocarboxylate Transporters MCT8 and MCT10.
Virus Diseases
ACE2 and gut amino acid transport.
Forecasting the timeframe of 2019-nCoV and human cells interaction with reverse engineering.